The transition is driven by the need for greater operational agility and cost-effectiveness. Single-use technologies reduce the need for complex cleaning validation, decrease cross-contamination risks, increase throughput, and allow for faster scale-up of vaccine and therapeutic production.
Tubing and filtration systems are the leading segments. Tubing serves as the operational basis for fluid transfer between unit operations, while filtration consumables (such as capsule filters) are critical for the purification and sterilization of high-value biomolecules.
There is a growing demand for "smart" consumables embedded with sensors. These components allow for real-time digital monitoring of critical process parameters such as pH, pressure, and dissolved oxygen, facilitating automated bioproduction and closed-loop control systems.
Contract Development and Manufacturing Organizations (CDMOs) and Clinical Research Organizations (CROs) are major drivers of demand. Because they operate multi-product facilities with compressed timelines, they rely on pre-validated, "plug-and-play" disposable consumables to achieve rapid changeover and minimize downtime.
Sustainability is becoming a strategic priority. Manufacturers are increasingly investing in the development of eco-friendly, biodegradable, or recyclable single-use alternatives through innovations in polymer science to balance sterility requirements with ecological responsibility.
North America currently holds the lead due to its extensive biopharma manufacturing base and early adoption of digital biomanufacturing. However, the Asia-Pacific region is the fastest-emerging market, fueled by significant investments in biologics and biotech innovation hubs in China, India, and South Korea.
Global health agencies like the U.S. FDA and EMA are increasingly endorsing single-use systems. They are providing specific guidance on the validation and qualification of these systems for aseptic processing, which helps standardize components and lowers the barrier to entry for manufacturers.
Advanced therapies often involve high-value, low-batch production that requires extreme sterility assurance. Single-use assemblies provide the necessary flexibility and scalability, making them the default infrastructure for the complex manufacturing requirements of cell and gene therapy pipelines.
Recent developments include Thermo Fisher Scientific’s launch of gamma-irradiated capsule filters for mRNA production, Sartorius AG’s facility expansion in Tunisia for sensors and connectors, Merck KGaA’s introduction of smart sampling systems, and Avantor’s acquisition of Masterflex to expand its precision fluid handling portfolio.
